A review on the impact of the worldwide shortage of glucagon-like peptide-1 medications on control of diabetic patients

Abrar A. Saiyed; Mohammed Q. Darr; Sahdia S. Ghulam

doi:10.18203/2394-6040.ijcmph20242990

Authors

Abrar A. Saiyed Department of Family Medicine, Primary Health Care Corporation, Doha, Qatar
Mohammed Q. Darr Department of Family Medicine, Primary Health Care Corporation, Doha, Qatar
Sahdia S. Ghulam Department of General Practice, Locum GP, London, UK

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20242990

Keywords:

GLP-1 RA, Shortage, Diabetes, Worldwide, Semaglutide, Ozempic®

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RA) have shown promising benefits in improving outcomes for patients with type 2 diabetes, particularly those affected by obesity-related complications such as cardiovascular disease, cardiometabolic disorders, and heightened cancer risks, posing significant public health challenges. Notably, GLP-1 RA have been recognized for their potential to achieve up to a 15% weight reduction over a span of two years, making them a preferred choice in specific conditions for diabetic patients with a body mass index (BMI) above 27. However, widespread public interest, particularly amplified through social media, has intensified the demand for GLP-1 RA due to their weight loss properties, thereby straining global supplies and fostering a black market among non-diabetic individuals seeking these effects. This heightened attention has prompted various medical regulatory bodies worldwide to enact strategies and policies aimed at alleviating shortages. Measures include minimizing new prescriptions of GLP-1 RA, exploring alternative medications within the GLP-1 RA category, carefully transitioning patients to other anti-diabetic treatments and managing patient expectations. These efforts appear effective in managing overall outcomes amid ongoing supply challenges. This narrative review provides a focused evaluation of how these GLP-1 RA medication shortages have impacted type 2 diabetic patients around the world and their overall diabetic outcomes.

Metrics

Metrics Loading ...

References

Elmaleh-Sachs A, Schwartz J, Bramante C, Nicklas J, Gudzune K, Jay M. Obesity Management in Adults: A Review. J Am Med Assoc. 2023;330(20):2000-15.

Mechanick J, Farkouh M, Newman J, Garvey W. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers JACC state-of-the-art review. J Am College Cardiol. 2020;75(5):525-38.

Garvey W, New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metabol. 2022;107(4):1339-47.

Sjostrom C, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after interventional weight loss induced by bariatric surgery: The SOS Intervention Study. Obesity Res.1999;7(5):477-84.

Wilson P, D’Agostino R, Sullivan L, Parise H, Kannel W. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Internal Med. 2002;162(16):1867-72.

Benjamin E, Levy D, Vaziri S, D’Agostino R, Belanger A, Wolf P. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J Am Med Assoc. 1994;271(11):840-4.

Colditz G, Willett W, Rotnitzky A, Manson J. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women. Ann Internal Med. 1995;122(7):481-6.

Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal Fasting Plasma Glucose Levels and Type 2 Diabetes in Young Men. N Eng J Med. 2005;353(14):1454-62.

Grundy S, Barnett J. Metabolic and health complications of obesity. Disease A Month. 1990;36(12):641-731

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17)2735-52.

Shetty S, Parthasarathy S. Obesity hypoventilation syndrome. Curr Pulmonary Rep. 2015;4(1):42-55.

Canargo C, Jr, Weiss S, Zhang S, Willett W, Speizer F. Prospective study of body mass index, weight change and risk of adult-onset asthma in women. Arch Internal Med. 1999;159(21):2582-8.

Bailey C, Flatt P, Conlon J. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023;161(1):170939.

Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152(7):1656-70.

Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obesity Metabol. 2023;25(4):961-4.

Han S, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, Furnas H, Sorice-Virk S. Public Interest in the Off-Label Use of Glucagon-Like Peptide 1 Agonists (Ozempic®) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthetic Surg J. 2023:44(1):60-7.

Bonner L. GLP-1 Receptor Agonists: Breaking down the Hype and Demand. American Pharmacists Association. 2023. Available at: https://pharmacist. com/Publications/Pharmacy-Today/Article/glp-1-receptor-agonists-breaking-down-the-hype-and-demand. Accessed on 11 April 2024.

Suran M. As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight Loss. J Am Med Assoc. 2023;329(19):1627-9.

Yang A. National Geographic. Ozempic Is a Serious Drug with Serious Risks. Here’s What to Know.2023. Available at: https://www.nationalgeographic.com/ science/article/ozempic-tiktoks-favorite-weight-loss-drug-is-unproven. Accessed on 11 April 2024.

Blum D. The New York Times. 2022. Available at: https://www.nytimes.com/2022/11/22/well/Ozempic-diabetes-weight-loss.html. Accessed on 11 April 2024.

Whitley H, Trujillo J, Neumiller J. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clin Diabetes. 2023;41(3):467-73.

FDA Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. 2024. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss. Accessed on 11 April 2024.

Putka S. Diabetes patients also struggle to access GLP-1 agonists: patients are making substitutions, crossing state lines, stopping care because of shortages. 2023. Available at: https://www.medpagetoday.com/special-reports/features/102773#:∼:text=All%20three%20of%20the%20most,loss%20and%20is%20expected%20to. Accessed on 10 March 2024.

Mailhac A, Pedersen L, Pottegard A, Sondergaard J, Mogensen T, Sorensen H, Thomsen R. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023-User Trends and off-Label Prescribing for Weight Loss. Clin Epidemiol. 2024;16(1);307-18.

U.S. Food and Drug Administration. FDA drug shortages. 2023 Available at: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm. Accessed on 10 March 2024.

Beba H, Ranns C, Hambling C, Diggle J, Brown P. PCDS consensus statement: a strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity. Diabetes Primary Care. 2022;24(5):147-9.

Long B, Pelletier J, Koyfman A, Bridwell R. GLP-1 agonists: A review for emergency clinicians. Am J Emergency Med. 2024;78(1) 89-94

Hantel A, Siegler M, Hlubocky F, Colgan K, Daugherty C. Prevalence and severity of rationing during drug shortages: a national survey of health system pharmacists. J Am Med Assoc. 2019;179(5):710-1.

Frías J, Bonora E, Nevarez Ruiz L. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765-73.

Frías J, Auerbach P, Bajaj H. Efficacy and safety of once weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabet Endocrinol. 2021;9(9):563-74.

Trujillo J, Nuffer W, Ellis S. GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Adv Endocrinol Metabol. 2015;6(1):19-28.

Novo Nordisk.Webpage.2023. Available at: https://www.novonordisk-us.com/supply-update.html. Accessed on 30 April 2024.

Pawlowski A, Wong C, Cohen M, Adams R, Gosk S. Canada cracks down on U.S. patients buying Ozempic in British Columbia. Webpage. 2023. Available at https://www.today.com/health/news /ozempic-weight-loss-canada-rcna77601. Accessed on 30 April 2024.

Government of Canada. Health Canada. Update on the supply of Ozempic and other GLP-1 receptor agonists: Notice. Webpage. 2023 Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html. Accessed on 30 April 2024.

Campbell P. Semaglutide Shortage Prompts FDA Warning to Patients, Providers. Webpage. 2023. Available at: https://www.hcplive.com/view/semaglutide-shortage-prompts-fda-warning-to-patients-providers. Accessed on 30 April 2024.

Panic G, Yao X, Gregory P, Austin Z. How do community pharmacies in Ontario manage drug shortage problems? Results of an exploratory qualitative study. Can Pharmacists J. 2020;153(6):371-7.

Skydsgaard N. Reuters. Novo Nordisk Says EMA Raised Safety Signal on Drugs Including Semaglutide. 2023. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-shares-slip-ema-drug-safety-signal-2023-06-22/. Accessed on 11 April 2024.

European Medicines Agency. Science Medicine Health. Shortage of Ozempic (Semaglutide) 2023. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss. Accessed on 11 April 2024.

Phakey S, Shen A. Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment. Aust J General Pract. 2024;53(1):57-61.

Massy-Westropp M. UNSW Sydney. What We Can Learn from the Ozempic Shortage. 2023. Available at: https://www.unsw.edu.au/newsroom/news/2023/02/what-we-can-learn-from-the-ozempic-shortage#:~:text=The%20Ozempic%20shortage%20illustrates%20the,current%20dearth%20of%20such%20medications. Accessed on 11 April 2024.

TGA about the Ozempic (Semaglutide) Shortage 2022 and 2023. 2023. Available at: https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-ozempic-semaglutide-shortage-2022-and-2023. Accessed on 11 April 2024.

Mattingly A. The role of outsourcing facilities in overcoming drug shortages. J Am Pharmac Assoc. 2021;61(1):110-14.

Arillota D, Floresta G, Guirguis A, Corkery J, Catalani V, Martinotti G, Sensi S, Schifano F. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023;13(11):1503.

Landsverk G. Shortages of a ‘game changer’ weight-loss drug are driving people to buy potentially risky knockoff versions. 2023. Available at: https://www.insider.com/buy-compounded-semaglutide-online-risks-wegovy-ozempic-2023-1. Accessed on 10 March 2024.

Belluz J. Obesity in the Age of Ozempic. 2023. Available at: https://www.vox.com/science-and-health/23584679/ozempic-wegovy-semaglutide-weight-loss-obesity. Accessed on 11 April 2024.

Davis N. The Guardian. New Diabetes Drugs Do Not Tackle Root Causes of Obesity, Experts Warn. 2023. Available at: https://www.theguardian.com/society/2023/feb/05/new-diabetes-drugs-do-not-tackle-root-causes-of-obesity-experts-warn. Accessed on 11 April 2024.

FDA Ozempic Prescribing Information. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637Orig1s009lbl.pdf. Accessed on 11 April 2024.

Nanayakkara N, Huang M, Jenkins A, Cohen N. The Impact of GLP-1 receptor agonist shortages on glycaemic control: Findings from an Australian specialist diabetic clinic. Diab Res Clin Pract. 2024;213(1):111740.